METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New alpha radiation therapy shows promise for tough prostate cancer
Disease control OngoingThis early-stage study tests a new drug called AB001, which delivers a powerful type of radiation directly to prostate cancer cells. The goal is to find a safe dose and see if it can shrink tumors in men with advanced prostate cancer that has stopped responding to hormone therapy…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: ARTBIO Inc. • Aim: Disease control
Last updated May 26, 2026 10:47 UTC
-
New hope for tough prostate cancer: combo therapy aims to delay disease worsening
Disease control OngoingThis study tests whether adding an experimental drug (PF-06821497) to standard enzalutamide works better than standard treatments alone for men with metastatic castration-resistant prostate cancer that has progressed after abiraterone. About 600 participants will be randomly assi…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New hope for men with advanced prostate cancer: radioactive drug vs standard therapy
Disease control OngoingThis study compares two treatments for men with prostate cancer that has spread to bones and is no longer responding to hormone therapy. One group receives radium-223, a radioactive drug that targets bone tumors, while the other continues with standard oral hormone drugs. The goa…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE4 • Sponsor: Bayer • Aim: Disease control
Last updated May 18, 2026 12:07 UTC